Pricing, patents and the PMPRB in Canada

The price of patented medicines in Canada is regulated by the Patented Medicine Prices Review Board (PMPRB), an independent, quasi-judicial body established under the Patent Act to ensure the prices of patented medicines are not excessive.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Teva and Aurinia settle generics dispute over lupus drug, voclosporin

21 August 2026 Under the terms of the agreement, which resolves all patent litigation between the biopharma rivals, Teva now has a launch date for its own version of Aurinia's Lupkynis.

Pharma

SK Biopharmaceuticals settles epilepsy generic dispute

20 August 2026 A reported deal with an Indian manufacturer could clear a path for a future generic launch as the Korean drugmaker leverages one of its biggest US products.

Pharma

Vanda revives challenge over braille-free label on generic sleep disorder drug

19 August 2026 Questions over braille on a generic sleep disorder drug label will face fresh scrutiny after an appeals court found fault with the FDA’s approach.

More features

Teva and Aurinia settle generics dispute over lupus drug, voclosporin

SK Biopharmaceuticals settles epilepsy generic dispute

Vanda revives challenge over braille-free label on generic sleep disorder drug

Europe’s missing biotech bridge: Why IP ownership matters more than capital access

Novartis scores UK win in high-stakes Entresto fight

The ‘Triple Point’ professional: Why patent success requires science, law, and technology

Lilly mounts defence as generics circle Mounjaro and Zepbound

Reading Stief, Haedicke and Wünsche, with the memory of a decade fought in Germany

Pricing, patents and the PMPRB in Canada

More on this story

Editor's picks

Editor's picks

More features